Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson’s Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Not all patients with Parkinson’s disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa.
Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia?
Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed.
Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model.
Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.
- Mutch W, Dingwall-Fordyce I, Downie A, et al. Parkinson’s disease in a Scottish city. BMJ 1986; 292: 534–6 CrossRef
- Schoenberg B, Andersen A, Haerer A. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35: 841–5 CrossRef
- Sutcliffe R, Prior R, Mawby B, et al. Parkinson’s disease in the district of Northampton Health Authority. Acta Neurol Scand 1985; 72: 363–79 CrossRef
- Sutcliffe R, Meara J. Parkinson’s disease epidemiology in Northampton District, England, 1992. Acta Neurol Scand 1995; 92 (6): 443–50 CrossRef
- Rajput A, Offord K, Beard C, et al. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984; 16: 278–82 CrossRef
- Gottwald M, Bainbridge J, Dowling G, et al. New pharmacotherapy for Parkinson’s disease. Ann Pharmacother 1997; 31 (10): 1205–17
- Stern MB. The changing standard of care in Parkinson’s disease: current concepts and controversies. Neurology 1997; 49 Suppl. 1: S1 CrossRef
- Kuzel M. Ropinirole: a dopamine agonist for the treatment of Parkinson’s disease. Am J Health Syst Pharm 1999; 56 (3): 217–24
- Watts R. The role of dopamine agonists in early Parkinson’s disease. Neurology 1997; 49 (1 Suppl. 1): S34–48 CrossRef
- Rascol O, Brooks D, Korczyn A, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–91 CrossRef
- Scheife R, Schumock G, Burnstein A, et al. Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000; 57 (10): 953–62
- Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997; 45 (7): 844–9
- Rubenstein L, Chrischilles E, Voelker M. The impact of Parkinson’s disease on health status, health expenditures, and productivity: estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997; 12 (4): 486–98 CrossRef
- Dodel R, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson’s disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14 (3): 299–312 CrossRef
- Hoerger T, Bala M, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson’s disease in the US. Pharmacoeconomics 1998; 14 (5): 541–57 CrossRef
- Hempel A, Wagner M, Maaty M, et al. Pharmacoeconomic analysis of using Sinemet CR over standard Sinement in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998; 32 (9): 878–89 CrossRef
- Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. The Canadian drug reference for health professionals. Toronto: Webcom Limited, 2002
- Shimomura SK. Parkinson’s disease. In: Katcher B, Young L, Koda-Kimble M, editors. Applied therapeutics. The clinical use of drugs. Spokane: Applied Therapeutics, Inc., 1983: 1113–26
- Schrag A, Brooks D, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson’s disease. Clin Neuropharmacol 1998; 21 (3): 169–75
- Statistics Canada. Latest release from the labour force survey. 2002 CANSIM tables 282-0001 to 282-0094. Available from URL: http://www.statcan.ca/english/Subjects/Labour/LFS/lfs-en.htm [Accessed 2002 Nov 21]
- Aoki FY, Fleming DM, Griffin AD, et al., on behalf of the Zanamivir Study Group. Impact of Zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Pharmacoeconomics 2000 Feb; 17 (2): 187–95. CrossRef
- Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson’s Disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997 Oct; 12 (4): 486–98 CrossRef
- Ontario Ministry of Health. Ontario drug benefit formulary/comparative drug index. 35 ed. Toronto: Ontario Ministry of Health, 1999
- Ontario Ministry of Health. Schedule of benefits: physician services under the health insurance act (1998 Feb 1). Toronto: Government of Ontario, 1998
- Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (6): 535–59 CrossRef
- Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson’s Disease
Volume 21, Issue 2 , pp 115-127
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors